Dear Reader,
"Hold onto your Tesla stock."
That's the message insiders at Tesla have been giving staff, as the world's biggest car firm prepares to launch a "mind blowing" new product.
It has nothing to do with EVs, or self-driving cars.
In fact, it's not a car at all... it's a radical pivot that could see the end of Tesla as we know it.
It could launch as soon as November 6, with Tesla insiders already flagging the date as a "critical inflexion point".
And when it does, the Tesla we all know could disappear forever.
In its place will be a company unlike anything any of us have ever seen. Insiders have even claimed the company is about to grow 3,000% - despite the fact it is already near record highs.
That's why – as the co-founder of a stock market research group that has been followed by professionals inside JP Morgan, Goldman Sachs, BlackRock and many of the world's biggest money managers – I'm stepping forward today...
I want to show you exactly what my research says is really going on inside Tesla...
Reveal whether you should buy or sell Tesla before November 6...
And give you the name and ticker of a company everyone is going to want to own when Tesla's dramatic pivot plays out.
I name it free of charge right here.
Best,
Rob Spivey
Research Director, Altimetry
Abbott Laboratories' October Price Plunge Is a Signal to Buy
Written by Thomas Hughes. Published 10/17/2025.
Key Points
- Abbott Laboratories' Q3 results did not catalyze a rally but also did not provide a reason to sell.
- Margin is solid, growth is present, and the capital return outlook is reliable.
- Analyst and institutional trends suggest these influential market groups will buy ABT on the dip.
Abbott Laboratories' (NYSE: ABT) October price plunge looks like a buying opportunity, as analyst and institutional trends indicate both groups are buyers. MarketBeat data show increasing analyst coverage, with new initiations appearing within days of the Q3 earnings release. Coverage is rising, sentiment has firmed over the past two quarters, and price targets are moving higher.
The consensus had forecast roughly a 10% gain ahead of the release — enough to reach a new all-time high — while the high end of analysts' ranges implies another roughly 10% upside.
"HELIOS": My No. 1 Investment of the 2020s (Ad)
A mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druckenmiller — just raised nearly $1 billion in funding. Early backers believe it could be one of the most impactful breakthroughs of our lifetime.
Whitney Tilson calls it "Helios" — and says a tiny Massachusetts firm sits at the center of what could become a global investment megatrend. If he's right, this could mark the start of a seismic shift in how the world powers its future.
Institutional investors have been steady buyers of this healthcare stock throughout the year. MarketBeat tracking shows institutions purchased about $1.50 for every $1.00 sold over the past 12 months, and that buying accelerated in the back half of the year — rising to roughly $3.25 bought for every $1.00 sold as of mid‑October. Institutions now own about 75% of outstanding shares, which provides a solid support base and a tailwind for price action visible on the charts.
The ABT chart reflects a market in a long-term uptrend that is consolidating ahead of its next meaningful move. The monthly view shows the stock pulling back from recent peaks but still in rebound mode, forming a Bullish Flag pattern after the October 2023 trend-line bounce and the price reversal confirmed earlier this year.
Abbott's price action may consolidate through year-end, but the setup points to higher levels in 2026, supported by growth, earnings quality, and capital returns. A move to new highs would be significant — breaking the current range and setting the stock up for roughly a $30, or about 30%, increase.
Abbott Laboratories Q3 Release Is No Reason to Sell This Stock
Abbott's Q3 report came in slightly below analysts' consensus, but the results do not justify selling the stock. Revenue growth missed consensus by only 0.17 percentage points; the company nevertheless reported 6.9% revenue growth and maintained solid margins (see analysis).
Foreign exchange, a headwind for many S&P 500 companies, was a tailwind for Abbott during the quarter, adding positively to revenue and earnings.
Revenue strength was led by the U.S. and international markets, with international sales up 9.9% and growth across three primary reporting segments. Diagnostics was the weak spot, down 7.8% organically, largely because COVID-19-related sales — noncore to the long-term business — declined.
Other segments performed well, with Medical Devices delivering 12.5% organic growth and Established Pharmaceuticals rising 7.1%.
Margin trends were encouraging. The company widened adjusted operating margin by 40 basis points, producing leveraged income growth. Operating income increased 10.6% and net income grew 7.5%, leaving adjusted EPS at $1.30 — in line with expectations and up roughly 7.5% year over year.
The key takeaway: Abbott's diversified business model supports sustained growth and healthy margins, underpinning a positive outlook for capital returns.
Abbott Laboratories' Dividend Is Reliable and Growing
Abbott's dividend is reliable and is expected to grow at a high-single- to low-double-digit pace for the foreseeable future.
The company is a Dividend King, with more than 50 consecutive years of annual increases. Its payout ratio is around 45% of earnings, and analysts expect meaningful earnings growth going forward.
Consensus estimates project Abbott's earnings to grow at a low-double-digit annual pace over the next five years — ample to support dividend increases without compromising the company's ability to reinvest in growth.
Abbott's diversified portfolio across diagnostics, medical devices, nutrition, and branded generics provides multiple revenue streams that help buffer the business against sector-specific slowdowns.
With a strong balance sheet and consistent cash flow, Abbott remains well positioned to fund growth initiatives while increasing shareholder returns.
This email communication is a sponsored email sent on behalf of Altimetry, a third-party advertiser of Earnings360 and MarketBeat.
This ad is sent on behalf of Altimetry, 110 Cambridge Street, Cambridge, MA 02141. If you would like to optout from receiving offers from Altimetry please click here.
If you have questions about your newsletter, please feel free to contact our U.S. based support team at contact@marketbeat.com.
If you no longer wish to receive email from Earnings360, you can unsubscribe.
© 2006-2025 MarketBeat Media, LLC. All rights protected.
345 North Reid Place, Suite 620, Sioux Falls, South Dakota 57103. USA..